[1]BRAY F,FERLAY J,SOERJOMATARAM I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J].CA Cancer J Clin,2018,68(6):394-424.
[2]SIEGEL RL,MILLER KD,JEMAL A.Cancer statistics,2020［J].CA Cancer J Clin,2020,70:7-30.
[3]JOHNSON DH,SCHILLER JH,BUNN PA.Recent clinical advances in lung cancer management［J].J Clin Oncol,2014,32(10):973-982.
[4]ZAROGOULIDIS P,TSAKIRIDIS K,KARAPANTZOU C,et al.Use of proteins as biomarkers and their role in carcinogenesis［J］.J Cancer,2015,6(1):9-18.
[5]SCHAFER BW,HEIZMANN CW.The S100 family of EF-hand calcium-binding proteins:functions and pathology［J］.Trends Biochem Sci,1996,21(4):134-140.
[6]CHEN H,XU C,JIN Q,et al.S100 protein family in human cancer［J］.Am J Cancer Res,2014,4(2):89-115.
[7]SUZUKI F,ORIDATE N,HOMMA A,et al.S100A2 expression as a predictive marker for late cervical metastasis in stage I and II invasive squamous cell carcinoma of the oral cavity［J］.Oncol Rep,2005,14(6):1493-1498.
[8]KYRIAZANOS ID,TACHIBANA M,DHAR DK,et al.Expression and prognostic significance of S100A2 protein in squamous cell carcinoma of the esophagus［J］.Oncol Rep,2002,9(3):503-510.
[9]FENG G,XU X,YOUSSEF EM,et al.Diminished expression of S100A2,a putative tumor suppressor,at early stage of human lung carcinogenesis［J］.Cancer Res,2001,61(21):7999-8004.
[10]OHUCHIDA K,MIZUMOTO K,MIYASAKA Y,et al.Over-expression of S100A2 in pancreatic cancer correlates with progression and poor prognosis［J］.J Pathol,2007,213(3):275-282.
[11]MCKIERNAN E,MCDERMOTT EW,EVOY D,et al.The role of S100 genes in breast cancer progression［J］.Tumour Biol,2011,32(3):441-450.
[12]IMAZAWA M,HIBI K,FUJITAKE S,et al.S100A2 overexpression is frequently observed in esophageal squamous cell carcinoma［J］.Anticancer Res,2005,25(2b):1247-1250.
[13]KWON YW,CHANG IH,KIM KD,et al.Significance of S100A2 and S100A4 expression in the progression of prostate adenocarcinoma［J］.Korean J Urol,2010,51(7):456-462.
[14]BULK E,SARGIN B,KRUG U,et al.S100A2 induces metastasis in non-small cell lung cancer［J］.Clin Cancer Res,2009,15(1):22-29.
[15]ZHANG Y,WANG H,WANG J,et al.Global analysis of chromosome 1 genes among patients with lung adenocarcinoma,squamous carcinoma,large-cell carcinoma,small-cell carcinoma,or non-cancer［J］.Cancer Metastasis Rev,2015,34(2):249-264.
[16]WANG H,ZHANG Z,LI R,et al.Overexpression of S100A2 protein as a prognostic marker for patients with stage I non small cell lung cancer［J］.Int J Cancer,2005,116(2):285-290.
[17]ZECH VF,DLASKA M,TZANKOV A,et al.Prognostic and diagnostic relevance of hnRNP A2/B1,hnRNP B1 and S100 A2 in non-small cell lung cancer［J］.Cancer Detect Prev,2006,30(5):395-402.
[18]MATSUBARA D,NIKI T,ISHIKAWA S,et al.Differential expression of S100A2 and S100A4 in lung adenocarcinomas:clinicopathological significance,relationship to p53 and identification of their target genes［J］.Cancer Sci,2005,96(12):844-857.
[19]HOUNTIS P,FOUKAS PG,MATTHAIOS D,et al.Prognostic significance of different immunohistochemical S100A2 protein expression patterns in patients with operable nonsmall cell lung carcinoma［J］.Onco Targets Ther,2012,5:363-373.
[20]DIEDERICHS S,BULK E,STEFFEN B,et al.S100 family members and trypsinogens are predictors of distant metastasis and survival in early-stage non-small cell lung cancer［J］.Cancer Res,2004,64(16):5564-5569.
[21]HOUNTIS P,MATTHAIOS D,FROUDARAKIS M,et al.S100A2 protein and non-small cell lung cancer.The dual role concept［J］.Tumour Biol,2014,35(8):7327-7333.
[22]STROUP DF,BERLIN JA,MORTON SC,et al.Meta-analysis of observational studies in epidemiology:a proposal for reporting.Meta-analysis of observational studies in epidemiology(MOOSE) group［J］.JAMA,2000,283(15):2008-2012.
[23]PARMAR MK,TORRI V,STEWART L.Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints［J］.Stat Med,1998,17(24):2815-2834.
[24]HIGGINS JP,THOMPSON SG.Quantifying heterogeneity in a meta-analysis［J］.Stat Med,2002,21(11):1539-1558.
[25]QIU ZX,ZHANG K,QIU XS,et al.The prognostic value of phosphorylated AKT expression in non-small cell lung cancer:a meta-analysis［J］.PLoS One,2013,8(12):e81451.
[26]KUMLER I,TUXEN MK,NIELSEN DL.A systematic review of dual targeting in HER2-positive breast cancer［J］.Cancer Treat Rev,2014,40(2):259-270.
[27]ZHAO Y,ZHANG TB,WANG Q.Clinical significance of altered S100A2 expression in gastric cancer［J］.Oncol Rep,2013,29(4):1556-1562.
[28]ZHA C,JIANG XH,PENG SF.iTRAQ-based quantitative proteomic analysis on S100 calcium binding protein A2 in metastasis of laryngeal cancer［J］.PLoS One,2015,10(4):e0122322.
[29]SATO Y,HARADA K,SASAKI M,et al.Clinicopathological significance of S100 protein expression in cholangiocarcinoma［J］.J Gastroenterol Hepatol,2013,28(8):1422-1429.
[30]LIU YF,LIU QQ,WANG X,et al.Clinical significance of S100A2 expression in gastric cancer［J］.Tumour Biol,2014,35(4):3731-3741.
[31]BIANKIN AV,KENCH JG,COLVIN EK,et al.Expression of S100A2 calcium-binding protein predicts response to pancreatectomy for pancreatic cancer［J］.Gastroenterology,2009,137(2):558-568,e551.
[32]BACHET JB,MARECHAL R,DEMETTER P,et al.S100A2 is a predictive biomarker of adjuvant therapy benefit in pancreatic adenocarcinoma［J］.Eur J Cancer,2013,49(12):2643-2653.